- Poster presentation
- Open Access
An obstacle to overcome: cerebral toxoplasmosis in patients living with HIV
© Filipescu et al; licensee BioMed Central Ltd. 2014
Published: 29 May 2014
Toxoplasmosis represents the most frequent complication affecting the CNS of AIDS patients.
In Europe and South America the prevalence of toxoplasmosis is higher than in the United States (50-75% to 15%), so the risk for the AIDS-associated toxoplasmosis is higher in this area, including Romania.
Most of the AIDS patients have immunoglobulin G antibodies anti-Toxoplasma in their serum, like in the general population, so most of the cases represent a reactivation of a latent infection.
We present a series of 5 cases with patients, aged between 19-29 years old, who developed cerebral toxoplasmosis.
Three of the patients are multi-experienced, and for two patients the cerebral toxoplasmosis was the defining AIDS infection.
Three patients had a CD4 count under 100 cells/cmm at the moment of their diagnosis, with low adherence for cART and for the prophylaxis with trimethoprim-sulfamethoxazole.
All patients but one had detectable HIV viral load.
Two of the patients are positive for B hepatitis, one of them also for hepatitis D.
The clinical manifestations were persistent headache, confusion, lethargy, hemiparesis.
All patients presented high levels for immunoglobulin G anti-Toxoplasma at the moment of the clinical manifestations, one patient presented immunoglobulin M anti-Toxoplasma.
The MRI examinations revealed characteristic multiple lesions.
The treatment was performed using trimethoprim-sulfamethoxazole for 6 weeks.
The evolution of the patients under the treatment was favorable for all the patients, with the remission of the symptoms and without neurological complications; they received trimethoprim-sulfamethoxazole prophylaxis until their CD4 >200/cmm, for another three months
Although difficult to diagnose, cerebral toxoplasmosis is treatable and curable, despite of all the associated AIDS pathology.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.